Monitor for future docket updates or public filings in this case. Given the lack of accessible information, no immediate trading action is warranted. Be cautious of potential information asymmetry if material details emerge later.
REGN drugs
REGN drug pipeline →- ● Otarmeni 3/10 Approved (accelerated approval) · BLA filing 2026
- ▲ Cemdisiran 6/10 Filed/PDUFA (Phase 3 NIMBLE complete; NDA under FDA Priority Review)
- ▲ Dupixent 4/10 Approved (marketed since 2017; additional Phase 3 trials ongoing for label expansion)
- ● Evkeeza 4/10 Approved
- ● EYLEA HD 4/10 Approved
- 12 more · All REGN drugs, catalysts & trials →
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Mar 30 $746.75entry
- T+1 · 8mo ago +3.12%α +0.23% · $770.08
- T+5 · 7mo ago +1.75%α −2.55% · $759.81
- T+20 · 7mo ago −2.33%α −14.93% · $729.36
- T+60 · 5mo ago −16.51%α −32.54% · $623.43
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Analysis based on filing metadata only, document content was unavailable. The case 'Fraioli v. Regeneron Pharmaceuticals, Inc.' was filed in the Southern District of Florida, but no substantive ruling or opinion text is accessible to assess the outcome, financial exposure, or business impact.
Court Ruling Details
Key Facts
- Case: Fraioli v. Regeneron Pharmaceuticals, Inc. et al, filed 2026-03-30 in the Southern District of Florida (Case No. 1:26-cv-20636)
- No ruling text or docket entries available, only a login redirect for PACER system
- Plaintiff is Fraioli; Regeneron is named as defendant
- Nature of suit or claims cannot be determined from available data
Financial Impact
Unknown, no information on damages, injunctions, or settlement
Risk Factors
- Potential for material undisclosed litigation risk if the case involves securities, product liability, or regulatory claims
- Low visibility increases uncertainty, which could lead to volatility if details are later disclosed
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 court opinion.
| Document | Accession Number |
|---|---|
| COURT-RULING Data (Synthetic) | court-iczfz1rr-REGN |
Track record
53 reports on REGN
11 of 17 bullish or bearish reports moved the stock their way by T+20. Best: +31.76% at T+20 after the Oct 6, 2026 report. 17 of 21 went positive at some point.
Filters
- Nov 16, 2026today 144 Neutral 2/10 Entry $951.23 Now $952.40 +0.12% settles Dec 16
- Nov 16, 2026today 144 Neutral 2/10 Entry $948.00 Now $952.40 +0.46% settles Dec 16
- Nov 12, 20264d ago Press Release Bullish 5/10 Entry $955.47 Now $952.40 −0.32% settles Dec 14
- Nov 5, 202611d ago Insider Cluster Neutral 2/10 Entry $904.35 Now $952.40 +5.31% settles Dec 7
- Nov 5, 202611d ago Insider Cluster Neutral 3/10 Entry $904.35 Now $952.40 +5.31% settles Dec 7
- Nov 4, 202612d ago 144 Neutral 1/10 Entry $902.90 Now $952.40 +5.48% settles Dec 4
- Nov 4, 202612d ago 144 Neutral 2/10 Entry $902.90 Now $952.40 +5.48% settles Dec 4
- Nov 3, 202613d ago Insider Cluster Neutral 2/10 Entry $930.67 Now $952.40 +2.33% settles Dec 3
- Nov 3, 202613d ago 144 Neutral 2/10 Entry $930.67 Now $952.40 +2.33% settles Dec 3
- Nov 3, 202613d ago Insider Cluster Neutral 2/10 Entry $930.67 Now $952.40 +2.33% settles Dec 3
US Market Status
Subscribe to SecBot
Get Real-Time Court Ruling Intelligence
Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more, parsed and scored by AI.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers